OGM | Jotup

Bionano Announces Robust Presence at Upcoming Cytogenetics Conferences ESHG and ACC with 39 Scientific Presentations and Posters Highlighting the Utility of the Optical Genome Mapping Workflow

Retrieved on:

星期四, 五月 30, 2024

ESHG brings together industry and academic professionals annually to discuss new technologies and advances in the field of human genetics.

Key Points:

ESHG brings together industry and academic professionals annually to discuss new technologies and advances in the field of human genetics.
ESHG sessions will take place June 1-4, 2024 virtually and in Berlin, Germany.
ACC is a biennial conference focused on new technologies and advances in the field of cytogenetics.
Dr. Gallagher will also introduce the latest innovations in the OGM workflow, including the Stratys system and VIA software.

Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy

Retrieved on:

星期二, 五月 21, 2024

Study results confirmed the vulnerability of genomic DNA to gene editing and highlighted the utility of OGM for genome-wide quality assessment of genetic engineering.

Key Points:

Study results confirmed the vulnerability of genomic DNA to gene editing and highlighted the utility of OGM for genome-wide quality assessment of genetic engineering.
“These studies highlight how researchers can use OGM when developing cell and gene therapies.
The expansion of gene therapy faces risks due to both on-target and off-target structural variations that may be introduced during genome editing.
To learn more about OGM’s utility in cell and gene therapy applications, please visit this website .

Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis

Retrieved on:

星期四, 五月 9, 2024

Cancer, OGM, Chord diagram (information visualization), Doctor of Philosophy, Aneuploidy, VIA, Classification, Genomics, SVS, SAN, Medical imaging

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis.

Key Points:

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis.
These advancements to the company’s VIA™ software solution enhance the detection and interpretation of aneusomies, and improve the analysis, visualization, interpretation, and reporting of data types including optical genome mapping (OGM), next generation sequencing, and microarray, for comprehensive assessment of hematological diseases.
These advancements to our VIA software and Bionano Solve pipeline offer researchers working with OGM data more precise and sensitive detection methods for genomic research.
We believe the upgrades announced today will improve researchers’ ability to visualize, interpret and report results in a streamlined process that offers greater utility for the identification of critical cancer signatures from a genome-wide perspective,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.

Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress

Retrieved on:

星期三, 五月 8, 2024

Reiterated full year 2024 revenue guidance of $37.0 to $41.0 million; revenue for the second quarter of 2024 is expected to be $7.8 to $8.2 million.

Key Points:

Reiterated full year 2024 revenue guidance of $37.0 to $41.0 million; revenue for the second quarter of 2024 is expected to be $7.8 to $8.2 million.
GAAP gross margin for the first quarter of 2024 was 32%, compared to 28% from the first quarter of 2023.
First quarter 2024 non-GAAP gross margin was 34%, compared to 30% from the first quarter of 2023.
Gülsen Kama, chief financial officer at Bionano added, “Q1 2024 was an important quarter for the Company.

Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing

Retrieved on:

星期三, 四月 24, 2024

Nanopore, Nanopore sequencing, OGM, University Medical Center, Doctor of Philosophy, Leukemia, BMA, Genomics, Bone marrow, SVS, SAN, University Medical Center Groningen

OGM has been shown to regularly detect SVs missed by other methods, as a result of the higher resolution and sensitivity of OGM.

Key Points:

OGM has been shown to regularly detect SVs missed by other methods, as a result of the higher resolution and sensitivity of OGM.
Some of OGM’s novel findings, however, are difficult for other methods to validate, because of their resolution limitations.
The study results highlight OGM’s ability to provide researchers with a more comprehensive understanding of leukemia subtypes and the potential of targeted Cas9-directed Nanopore sequencing to validate new findings efficiently and at high resolution, compared to other genome analysis methods, including short read or other long read sequencing methods.
“We were pleased to see researchers conclude that the findings detected by OGM in leukemia samples were robust and superior to classical cytogenetic methods.

Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence

Retrieved on:

星期三, 四月 17, 2024

Cytogenetics, Pregnancy, NMPA, OGM, Partnership, OEM, Doctor of Philosophy, Research, Artificial intelligence, Karyotype, Fertilisation, Genomics, Bone marrow, SVS, SAN, Medical device

Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology.

Key Points:

Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology.
Diagens has received Class I registration and approval for Bionano’s OGM reagents from China's NMPA and will register the Saphyr™ instrument with NMPA for clinical use in reproductive health.
“As a pioneer in AI chromosome karyotype analysis, we are very happy to establish a partnership with Bionano and to jointly explore the reproductive health market.
Diagens offers cutting-edge AI technology to help our customers to achieve a better overall success rate of in vitro fertilization.

Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing

Retrieved on:

星期四, 四月 11, 2024

B-ALL, OGM, RNA, WGS, Genetic variation, Doctor of Philosophy, Research, Leukemia, Bone marrow, Biomarker, Genomics, Whole genome sequencing, Cancer, SVS, SAN, Vaccine

The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches side-by-side and the potential benefit of integrating WGS and OGM to obtain a comprehensive analysis of genetic variation.

Key Points:

The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches side-by-side and the potential benefit of integrating WGS and OGM to obtain a comprehensive analysis of genetic variation.
The study concluded that OGM together with WGS can potentially identify new therapeutic targets and improve personalized medicine in pediatric leukemia and other cancers by providing a more complete view of genome variation, including structural variation.
The study findings showed that, of the 3,075 total SVs detected in the B-ALL samples, 1,255 were uniquely detected by OGM.
The study also found that WGS detected 66 gene fusions, and that OGM was able to detect an additional 56 fusions that were missed by WGS.

Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics

Retrieved on:

星期三, 四月 3, 2024

Sarcoma, Diagnosis, KT, Oncogene, SAN, Neoplasm, Research, Cancer, Doctor of Philosophy, CDKN2A, Workflow, Karyotype, FISH, Genomics, Chromothripsis, SVS, Prognosis, Aberration, OGM, Medical imaging

Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.

Key Points:

Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.
The detection of SVs and CNVs remains challenging and typically requires multiple traditional cytogenetic techniques.
In this study, researchers demonstrated OGM’s ability to detect aberrations as small as 500 bp, which is approximately 10,000-fold higher resolution than that of KT.
As shown in this study, OGM can provide better characterization of the genomic complexity of sarcoma samples when compared to traditional cytogenetic techniques, due to the workflow’s high resolution and comprehensive, genome-wide analysis.

Bionano Announces 9 Poster Presentations and Introduces New High Throughput Stratys™ System at the American Association for Cancer Research Annual Meeting

Retrieved on:

星期二, 四月 2, 2024

SAN, NGS, Research, Classification, Cancer, Software, AACR, Genomics, VAF, Bone marrow, OGM, VIA, Medicine, Medical imaging

AACR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine.

Key Points:

AACR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine.
The AACR conference will be held April 5-10, 2024, in San Diego, California.
Bionano will introduce its new Stratys™ system, which offers higher throughput and improved sample flexibility, to the cancer research community at the conference.
Nine scientific poster presentations will illustrate OGM’s utility for cancer research in areas including solid tumors, hematological malignancies, as well as applications in cell and gene therapy and cell manufacturing and bioprocessing quality control.

Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Retrieved on:

星期二, 三月 19, 2024

Ovarian cancer, DNA repair, Breast, SAN, Neoplasm, DNA, HBOC, Doctor of Philosophy, Medicine, Genomics, Chromothripsis, SVS, Breast cancer, HRD, BRCA2, OGM, BRCA1, Drug resistance, Medical imaging

HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.

Key Points:

HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.
The study authors selected OGM for this analysis due to its ability to detect multiple classes of SVs with genome-wide coverage, high resolution and accuracy.
Eight novel gene fusions were identified by OGM, including three that had not previously been detected by other methods of analysis.
“We are pleased to see the publication of this study, which highlights OGM as a promising tool for detecting novel variants in HBOC-related breast cancer that have oncogenic potential.